The present invention relates to the production of benzene derivatives from furfural and its derivatives. The present invention also relates to the preparation of novel intermediates derived from furfural and its derivatives. The present invention describes new routes for converting furfural and its derivatives into benzene derivatives including novel intermediates.

The present invention relates to the production of benzene derivatives from furfural and its derivatives. The present invention also relates to the preparation of novel intermediates derived from furfural and its derivatives. The present invention describes new routes for converting furfural and its derivatives into benzene derivatives including novel intermediates.

Enediyne compounds having a structure according to formula (I), where R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and X are defined herein.

##STR00001##

Enediyne compounds having a structure according to formula (I), where R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and X are defined herein.

##STR00001##

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

In one aspect, the present disclosure relates to compounds and compositions capable of inhibiting TACC3. In another aspect, the present disclosure relates to methods of treating TACC3 mediated diseases and disorders.

In one aspect, the present disclosure relates to compounds and compositions capable of inhibiting TACC3. In another aspect, the present disclosure relates to methods of treating TACC3 mediated diseases and disorders.

The present invention provides an antitumor agent comprising a compound or a pharmaceutically acceptable salt thereof that covalently binds to GTP-bound KRASG12C as an active ingredient.

The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

##STR00001##

The present invention relates to a 6-6 bicyclic ring-containing compound derivative and use thereof. The compound according to the present invention acts as a PRMT5 inhibitor, and thus can be effectively used in the prevention or treatment of diseases caused by PRMT5.